Abstract: This invention relates to pyrimidine derivatives of general formula I in which R1, R2, X, A and B have the meanings that are contained in the description, as inhibitors of the cyclin-dependent kinases, their production as well as their use as medications for treating various diseases.

Abstract: This invention relates to novel compounds suitable for labelling or already labelled by 18F, methods of preparing such a compound, compositions comprising such compounds, kits comprising such compounds or compositions and uses of such compounds, compositions or kits for diagnostic imaging by positron emission tomography (PET).

Abstract: The present invention relates to novel compounds suitable for or already radiolabelled with 18F, methods of making such compounds and use of such compounds for diagnostic imaging.

Abstract: The present invention relates to novel compounds suitable for or already radiolabeled with 18F, methods of making such compounds and use of such compounds for diagnostic imaging. Such labeled compounds are characterized by Formula II, wherein the substituents G, Q, L, Y and U have the meaning as defined in the specification and claims.

Abstract: This invention relates to pyrimidine derivatives of general formula I in which R1, R2, X, A and B have the meanings that are contained in the description, as inhibitors of the cyclin-dependent kinases, their production as well as their use as medications for treating various diseases.

Abstract: This invention relates to pyrimidine derivatives of general formula I in which R1, R2, X, A and B have the meanings that are contained in the description, as inhibitors of the cyclin-dependent kinases, their production as well as their use as medications for treating various diseases.

Abstract: The invention relates to the subjects that are characterized in the claims, namely perfluoroalkyl-containing metal complexes with nitrogen-containing radicals of general formula I, process for their production and their use in NMR and x-ray diagnosis, radiodiagnosis, and radiotherapy, as well as in MRT lymphography and in blood-pool imaging.

Abstract: This invention relates to pyrimidine derivatives of general formula I in which R1, R2, X, A and B have the meanings that are contained in the description, as inhibitors of the cyclin-dependent kinases, their production as well as their use as medications for treating various diseases.

Abstract: The invention relates to the subjects that are characterized in the claims, namely perfluoroalkyl-containing metal complexes with an N-alkyl group of general formula 1, process for their production and their use in NMR and x-ray diagnosis, radiodiagnosis, and radiotherapy, as well as in MRT lymphography.

Abstract: The invention relates to hydroxypyridinone derivatives, their metal complexes, their preparation and their use for preparing conjugates with biomolecules. The conjugates are suitable as contrast agents in NMR diagnosis. A high relaxivity is achieved and the NMRD maximum is raised through a specific design of the ligands.

Abstract: The invention relates to conjugates of hydroxypyridinone derivative metal complexes and to their preparation. The conjugates are suitable as contrast agents in NMR diagnosis. A high relaxivity is achieved and the NMRD maximum is raised through a specific design of the ligands.

Abstract: This invention relates to pyrimidine derivatives of general formula I 1

Abstract: Enantiomer-pure compounds of general formulas VIIa and VIIb 1

Abstract: This invention relates to pyrimidine derivatives of general formula I 1

Abstract: The invention relates to the compounds of Formula I as well as the process for their production and their use as pharmaceutical agents.

Abstract: Glucocorticoids of general formula IR--Val--O--GC (II),are described,in whichO-GC is the radical of a 21-hydroxycorticoid that has an antiinflammatory action,Val represents a valine radical in the 21-position of the corticoid andR means a hydrogen atom or a hydrocarbon radical with up to 32 carbon atoms that is optionally substituted by hydroxy groups, amino groups, oxo groups and/or halogen atoms and/or interrupted by oxygen atoms, SO.sub.2 groups and/or NH groups and their salts.

Abstract: 8.alpha.-acylamino ergolines are useful dopamine agonists.

Abstract: The invention concerns LHRH antagonists of the general formula (I),X-X.sub.1 -X.sub.2 -X.sub.3 -L-Ser-L-Tyr-X.sub.6 -L-Leu-X.sub.8 -L-Pro-X.sub.10 (I)The invention concerns LHRH antagonists of the general formula (I), in which X is an acyl group, X.sub.1 is a D-Nal, X.sub.2 is D-(4-Cl)-Phe, X.sub.3 is D-(3)-Pal, X.sub.6 is D-Cit or D-Neu, X.sub.8 is L-Arg or L-Neu, at least one of the groups X.sub.6 and X.sub.8 being a Neu, and X.sub.10 is D-Ala-NH.sub.2, Neu being a group of formula (II), (IV), (IX) or (X), wherein W is one of the group (a)-(d). The invention includes drugs containing a compound of formula (I), plus the usual auxiliaries and carriers. These drugs are suitable for use in cases of carcinoma of the prostate and in endometriosis, as well as for fertility control.

Abstract: Compounds of formula I and their acid addition salts ##STR1## in which R.sup.2 R.sup.6 R.sup.13 and X have the meanings defined herein are described as well as a process and intermediates for their production, and pharmaceutical agents containing these compounds.

Abstract: Compounds of formula I ##STR1## in which R.sup.2 means optionally substituted C.sub.1-7 alkyl, C.sub.2-7 alkenyl, CH.sub.2 --O--C.sub.1-4 alkyl or CH.sub.2 --S--C.sub.1-4 alkylR.sup.6 means C.sub.2-6 alkyl, C.sub.3-6 alkenyl or C.sub.3-5 -cycloalkyl-C.sub.1-2 alkyl andR.sup.8 means CH.sub.2 --X, ##STR2## in which X stands for CN, OCH.sub.3, SCH.sub.3 or CONH.sub.2 and R.sup.1 stands for hydrogen, halogen, methyl or methoxy, and R.sup.3 and R.sup.4 each mean C.sub.1-4 alkyl or (CH.sub.2).sub.n --N(CH.sub.3).sub.2, in which n=1-4, and their acid addition salts, the process for their production, their use as pharmaceutical agents as well as intermediate compounds are described.